WIN-Partners (3183) Fundamentals 2026 — P/E 17.4x, Revenue Analysis | SniperIQ
WIN-Partners (3183) is a JP-listed Healthcare company in Medical - Distribution with a market capitalization of ¥36.4B, trading at ¥1323.00 on the JPX. This SniperIQ fundamentals page covers WIN-Partners's valuation (P/E 17.4x, P/B 1.6x), profitability (net margin 2.3%), revenue (¥90.4B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is WIN-Partners's market cap?
WIN-Partners (3183) has a market capitalization of approximately ¥36.4B, trading at ¥1323.00 on the JPX. Market cap moves with the live share price.
What is WIN-Partners's P/E ratio?
WIN-Partners's trailing twelve-month P/E ratio is 17.4x, with a price-to-book (P/B) of 1.6x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is WIN-Partners?
WIN-Partners runs a net profit margin of 2.3%, a gross margin of 11.8%, and an operating margin of 3.3%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does WIN-Partners generate?
WIN-Partners reported revenue of ¥90.4B for fiscal year 2025, with net income of ¥2.1B and earnings per share (EPS) of 75.98. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does WIN-Partners pay a dividend?
WIN-Partners offers a trailing dividend yield of about 4.1%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is WIN-Partners financially healthy?
WIN-Partners carries a debt-to-equity ratio of 0.03x and a current ratio of 1.70x, with a market beta of 0.18. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is WIN-Partners a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For WIN-Partners (3183) the key facts are: market cap ¥36.4B, P/E 17.4x, revenue ¥90.4B, 52-week range 1175-1527. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track WIN-Partners's full fundamentals live
Get WIN-Partners's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.